Kenneth E Lipson

List of Publications by Year
in descending order

79	4,630	87843 38	98753 67
papers	citations	h-index	g-index

80	80	80	6667
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Connective-Tissue Growth Factor Contributes to TGF-Î²1â€“induced Lung Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2022, 66, 260-270.	1.4	45
2	Driving fibrosis in neuromuscular diseases: Role and regulation of Connective tissue growth factor (CCN2/CTGF). Matrix Biology Plus, 2021, 11, 100059.	1.9	18
3	Role of hypoxia in skeletal muscle fibrosis: Synergism between hypoxia and TGF-Î² signaling upregulates CCN2/CTGF expression specifically in muscle fibers. Matrix Biology, 2020, 87, 48-65.	1.5	45
4	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 272-285.	2.9	182
5	Connective Tissue Growth Factor Inhibition Enhances Cardiac Repair and Limits Fibrosis After Myocardial Infarction. JACC Basic To Translational Science, 2019, 4, 83-94.	1.9	48
6	Denervation-induced skeletal muscle fibrosis is mediated by CTGF/CCN2 independently of TGF-Î². Matrix Biology, 2019, 82, 20-37.	1.5	52
7	Plasma Connective Tissue Growth Factor (CTGF/CCN2) Levels Predict Myocardial Infarction in the Veterans Affairs Diabetes Trial (VADT) Cohort. Diabetes Care, 2018, 41, 840-846.	4.3	18
8	Vascular Endothelial Cell-Specific Connective Tissue Growth Factor (CTGF) Is Necessary for Development of Chronic Hypoxia-Induced Pulmonary Hypertension. Frontiers in Physiology, 2018, 9, 138.	1.3	26
9	Radiation-induced pulmonary gene expression changes are attenuated by the CTGF antibody Pamrevlumab. Respiratory Research, 2018, 19, 14.	1.4	18
10	Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC. Radiation Oncology, 2018, 13, 1.	1.2	73
11	The inhibition of CTGF/CCN2 activity improves muscle and locomotor function in a murine ALS model. Human Molecular Genetics, 2018, 27, 2913-2926.	1.4	29
12	Effects of CTGF Blockade on Attenuation and Reversal of Radiation-Induced Pulmonary Fibrosis. Journal of the National Cancer Institute, 2017, 109, .	3.0	106
13	Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis. Scientific Reports, 2017, 7, 5392.	1.6	63
14	Anti-connective tissue growth factor (CTGF/CCN2) monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosis. Arthritis Research and Therapy, 2017, 19, 134.	1.6	63
15	FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition. Pharmaceutical Research, 2016, 33, 1833-1849.	1.7	26
16	ERK1/2 directly acts on CTGF/CCN2 expression to mediate myocardial fibrosis in cardiomyopathy caused by mutations in the lamin A/C gene. Human Molecular Genetics, 2016, 25, 2220-2233.	1.4	76
17	Connective tissue growth factor regulates cardiac function and tissue remodeling in a mouse model of dilated cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2015, 89, 214-222.	0.9	25
18	Synergistic effects of crizotinib and radiotherapy in experimental EML4â€“ALK fusion positive lung cancer. Radiotherapy and Oncology, 2015, 114, 173-181.	0.3	43

#	Article	IF	Citations
19	Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors. Oncotarget, 2015, 6, 4663-4676.	0.8	62
20	Multimodal Therapies for Pancreatic Cancer. , 2014, , 39-73.		0
21	Connective Tissue Growth Factor Inhibition Attenuates Left Ventricular Remodeling and Dysfunction in Pressure Overloadâ€“Induced Heart Failure. Hypertension, 2014, 63, 1235-1240.	1.3	75
22	Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy. Human Molecular Genetics, 2013, 22, 4938-4951.	1.4	118
23	Anti-Connective Tissue Growth Factor Antibody Treatment Reduces Extracellular Matrix Production in Trabecular Meshwork and Lamina Cribrosa Cells. , 2013, 54, 7836.		56
24	CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis and Tissue Repair, 2012, 5, S24.	3.4	453
25	Connective Tissue Growth Factor Antibody Therapy Attenuates Hyperoxia-Induced Lung Injury in Neonatal Rats. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 1169-1177.	1.4	63
26	Development of the First Generation c-Met Kinase Inhibitors: Beginning of a Path to a New Treatment for Cancer. Molecular Cancer Therapeutics, 2011, 10, 2022-2023.	1.9	0
27	Potentiation of the antitumor effects of imidazoquinoline immune response modifiers by cyclophosphamide. Cancer Biology and Therapy, 2010, 10, 155-165.	1.5	17
28	NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. Cancer Immunology, Immunotherapy, 2009, 58, 575-587.	2.0	27
29	Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model. Radiation Oncology, 2009, 4, 66.	1.2	53
30	SU11657 Enhances Radiosensitivity of Human Meningioma Cells. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1213-1218.	0.4	9
31	Comparison of human B cell activation by TLR7 and TLR9 agonists. BMC Immunology, 2008, 9, 39.	0.9	103
32	TLR7 Agonist 852A Inhibition of Tumor Cell Proliferation Is Dependent on Plasmacytoid Dendritic Cells and Type I IFN. Journal of Interferon and Cytokine Research, 2008, 28, 253-263.	0.5	32
33	Combination of Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor Inhibition Markedly Improves Radiation Tumor Therapy. Clinical Cancer Research, 2008, 14, 2210-2219.	3.2	125
34	TLRâ€“TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-Î±. International Immunopharmacology, 2007, 7, 1111-1121.	1.7	90
35	Inhibition of in vitro tumor cell proliferation by cytokines induced by combinations of TLR or TLR and TCR agonists. International Immunopharmacology, 2007, 7, 1471-1482.	1.7	5
36	Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Review of Vaccines, 2007, 6, 835-847.	2.0	72

#	Article	IF	Citations
37	Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists. BMC Immunology, 2007, 8, 26.	0.9	66
38	Adventitial Microvessel Formation After Coronary Stenting and the Effects of SU11218, a Tyrosine Kinase Inhibitor. Journal of the American College of Cardiology, 2006, 47, 1067-1075.	1.2	37
39	Immune response modifiers: Imiquimod and future drugs for modulating the immune response. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 343-352.	0.5	4
40	Human Glioblastoma and Carcinoma Xenograft Tumors Treated by Combined Radiation and Imatinib (GleevecÂ®). Strahlentherapie Und Onkologie, 2006, 182, 400-407.	1.0	45
41	Small molecule receptor tyrosine kinase inhibitor of platelet-derived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells. BMC Cancer, 2006, 6, 79.	1.1	45
42	Trimodal Cancer Treatment: Beneficial Effects of Combined Antiangiogenesis, Radiation, and Chemotherapy. Cancer Research, 2005, 65, 3643-3655.	0.4	171
43	Inhibition of Î±vÎ²3 Integrin Survival Signaling Enhances Antiangiogenic and Antitumor Effects of Radiotherapy. Clinical Cancer Research, 2005, 11, 6270-6279.	3.2	210
44	Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. Journal of Experimental Medicine, 2005, 201, 925-935.	4.2	345
45	The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene, 2004, 23, 5387-5393.	2.6	170
46	Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1220-1232.	0.4	58
47	The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression. Lung Cancer, 2004, 46, 283-291.	0.9	38
48	Enhancing radiation-induced inhibition of angiogenesis and tumor growth by an alpha-V-beta-3 integrin receptor antagonist. International Journal of Radiation Oncology Biology Physics, 2003, 57, S319-S320.	0.4	2
49	Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-CÎ”NÎ”C- and VEGF-A-induced angiogenesis in vitro. Experimental Cell Research, 2003, 285, 286-298.	1.2	39
50	Blockade of Vascular Endothelial Growth Factor Receptor I (VEGF-RI), but not VEGF-RII, Suppresses Joint Destruction in the K/BxN Model of Rheumatoid Arthritis. Journal of Immunology, 2003, 171, 4853-4859.	0.4	121
51	The STE20 Kinase HGK Is Broadly Expressed in Human Tumor Cells and Can Modulate Cellular Transformation, Invasion, and Adhesion. Molecular and Cellular Biology, 2003, 23, 2068-2082.	1.1	103
52	SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Research, 2003, 63, 3755-63.	0.4	124
53	Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Research, 2003, 63, 8890-8.	0.4	125
54	Application of LC/MS/MS in the quantitation of SU101 and SU0020 uptake by 3T3/PDGFr cells. Journal of Pharmaceutical and Biomedical Analysis, 2002, 28, 701-709.	1.4	13

#	Article	IF	Citations
55	Receptor Tyrosine Kinases in Angiogenesis. , 2002, , 409-452.		2
56	Weekly Dosing With the Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor SU9518 Significantly Inhibits Arterial Stenosis. Circulation Research, 2001, 88, 630-636.	2.0	54
57	Merged Screening for Human Immunodeficiency Virus Tat and Rev Inhibitors. Journal of Biomolecular Screening, 2001, 6, 179-187.	2.6	8
58	Identification of Substituted 3-[(4,5,6,7-Tetrahydro-1H-indol-2-yl)methylene]- 1,3-dihydroindol-2-ones as Growth Factor Receptor Inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-RÎ² Tyrosine Kinases. Journal of Medicinal Chemistry, 2000, 43, 2655-2663.	2.9	112
59	Inhibition Of Vascular Endothelial Growth Factor (Vegf) And Stem- Cell Factor (Scf) Receptor Kinases As Therapeutic Targets For The Treatment Of Human Diseases. , 2000, , .		0
60	Carboxy-Substituted Cinnamides:â€‰ A Novel Series of Potent, Orally Active LTB4 Receptor Antagonists. Journal of Medicinal Chemistry, 1999, 42, 164-172.	2.9	19
61	Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Discovery Today, 1997, 2, 50-63.	3.2	72
62	N-aryl cinnamides: A novel class of rigid and highly potent leukotriene B4 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 949-954.	1.0	9
63	A Solid-Phase Assay for the Determination of Protein Tyrosine Kinase Activity of c-src Using Scintillating Microtitration Plates. Analytical Biochemistry, 1996, 234, 23-26.	1.1	61
64	Measurement of the Protein Tyrosine Kinase Activity of c-src Using Time-Resolved Fluorometry of Europium Chelates. Analytical Biochemistry, 1996, 238, 159-164.	1.1	64
65	CCAAT-box contributions to human thymidine kinase mRNA expression. Journal of Cellular Biochemistry, 1995, 57, 701-710.	1.2	4
66	Protein that binds to the distal, but not to the proximal, CCAAT of the human thymidine kinase gene promoter. Journal of Cellular Biochemistry, 1995, 57, 711-723.	1.2	2
67	Endothelin-I induces gene expression through stimulation of endothelin type a receptors in normal rat kidney cells. Journal of Cellular Physiology, 1995, 164, 491-498.	2.0	4
68	Two zinc-dependent steps during G1 to S phase transition. Journal of Cellular Physiology, 1993, 155, 445-451.	2.0	34
69	CGS 27830, a potent nonpeptide endothelin receptor antagonist. Bioorganic and Medicinal Chemistry Letters, 1993, 3, 2099-2104.	1.0	19
70	Unusual DNA binding characterstics of anin vitrotranslation product of the CCAAT binding protein mYB-1. Nucleic Acids Research, 1992, 20, 601-606.	6.5	35
71	Sequence analysis of the human thymidine kinase gene promoter: comparison with the human PCNA promoter. DNA Sequence, 1990, 1, 13-23.	0.7	11
72	GENE EXPRESSION AT THE G1/S BOUNDARY. , 1990, , 139-153.		0

#	Article	IF	Citations
73	Divalent cations regulate glucagon binding. Evidence for actions on receptor-Ns complexes and on receptors uncoupled from Ns. Biochemistry, 1988, 27, 1111-1116.	1.2	9
74	Regulation of the Expression of Cell Cycle Genes. Annals of the New York Academy of Sciences, 1988, 551, 283-289.	1.8	6
75	Effect of growth hormone on protein phosphorylation in isolated rat hepatocytes. Biochemistry, 1987, 26, 715-721.	1.2	14
76	Structure and proteolysis of the growth hormone receptor on rat hepatocytes. Biochemistry, 1987, 26, 4438-4443.	1.2	32
77	Characterization of glucagon receptors in Golgi fractions of rat liver: evidence for receptors that are uncoupled from adenylyl cyclase. Biochemistry, 1986, 25, 2612-2620.	1.2	13
78	N-Ethylmaleimide uncouples the glucagon receptor from the regulatory component of adenylyl cyclase. Biochemistry, 1986, 25, 5678-5685.	1.2	13
79	Receptor Tyrosine Kinases in Angiogenesis. , 0, , 409-452.		0